Route Development: Designing synthesis for GMP production

Success Beyond Science

« Back to Case Studies

Route Development: Designing synthesis for GMP production

Rapid development of readily scalable and robust synthesis

Planning early in the pipeline: Designing synthesis to suit later stages

The successful transition from initial synthesis of an API to a kilogram-scale route requires expert analysis and design. In addition to optimizing each intermediate reaction, chemists must balance economic, regulatory and time constraints. Furthermore, designing the best synthesis route for GLP and GMP production cannot begin without adequate knowledge of the compound, and it may require high-purity intermediates. Each API presents a unique set of challenges.

These barriers do not stall Avista Pharma from delivering on time. State-of-the-art facilities armed with world class experts and vast experience drive our success in designing the best synthetic route for each API. In this case study, our experts developed a robust, high-yield process to enable GMP production under tight time pressure for a first-in-human clinical trial.

It is not unusual for compounds to be received with very little chemical knowledge. Full characterization of the compound is required before beginning route development in order to ensure success. For this API, the team also had to address excessive levels of palladium (~10,000 ppm) that were historically reduced during chromatography in the medicinal chemistry process.

Medicinal chemistry routes are not optimized to meet regulation standards for purity, and they often involve chromatography steps that must be eliminated in order to be scalable. Our experts developed a unique approach to remove palladium during two reaction steps without the use of expensive scavengers. The level of palladium in the final API was reduced to 10-20 ppm without the use of chromatography.

Another component of optimal route design is controlling impurity formation in each step of synthesis while optimizing yield. Ideally, chemists seek to balance efficient chemistry with ease in purification and alignment with ICH guidelines. In this case, the redesigned route allowed control over impurities in both the process and starting material, and produced a yield of 87%. Moreover, our team exceeded expectations by developing the crystallization process for the final API salt in addition to the modifications to synthesis.

The design of an API synthesis route can be either a limiting factor or boost production, depending on how well it’s done. By applying our expertise and innovation, Avista Pharma delivered a suitable route for GLP and GMP production along with high-purity intermediates and crystallization of the API under a tight timeline.

 

Success beyond science.

Download a PDF of this case study.

 

Interested in learning more about Avista Pharma and how we can help you succeed? Contact Us